title: A novel dual function retrovirus expressing multidrug resistance 1 and O6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents.
abstract: Following transduction with a retrovirus (SF1MIH) expressing both the multidrug resistance 1 (MDR1) and O6-alkylguanine-DNA-alkyltransferase (ATase) proteins, human erythroleukaemic progenitor (K562) cells were isolated which were resistant to killing by the MDR1 substrate, colchicine. In colony-forming survival assays, K562-SF1MIH cells exhibited resistance to colchicine and doxorubicin, as well as to the O6-alkylating agents N-Methyl-N-nitrosourea (MNU) and temozolomide. Furthermore, the resistance to doxorubicin was abolished by preincubation with the MDR1 inhibitor verapamil while resistance to MNU was ablated by the specific ATase inactivator, O6-benzylguanine (O6-beG) confirming that resistance to doxorubicin and MNU was conferred by MDR1 and ATase, respectively. When K562-SF1MIH were exposed to combinations of colchicine and MNU or doxorubicin and temozolomide, simultaneous resistance to these agents was observed. Thus, transduction of K562 with SF1MIH conferred dual resistance to these cells. These data offer the prospect of designing vectors that will confer resistance to entire regimens of chemotherapy rather than just to individual components of such drug cocktails, thereby substantially increasing the efficacy of therapy. Furthermore, the use of such dual expression constructs is likely to be highly informative for the design of effective in vivo selection protocols, an issue likely to make a major impact in a clinical context in gene therapy in the near future.
authors.affiliation: Institute of Haematology and Blood Transfusion, Praha, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Jelinek
authors.forename: J A
authors.initials: JA
authors.lastname: Rafferty
authors.forename: R
authors.initials: R
authors.lastname: Cmejla
authors.forename: M
authors.initials: M
authors.lastname: Hildinger
authors.forename: D
authors.initials: D
authors.lastname: Chinnasamy
authors.forename: L S
authors.initials: LS
authors.lastname: Lashford
authors.forename: W
authors.initials: W
authors.lastname: Ostertag
authors.forename: G P
authors.initials: GP
authors.lastname: Margison
authors.forename: T M
authors.initials: TM
authors.lastname: Dexter
authors.forename: L J
authors.initials: LJ
authors.lastname: Fairbairn
authors.forename: C
authors.initials: C
authors.lastname: Baum
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D019450:Genes, MDR / Q000235:genetics; D005822:Genetic Vectors; D006412:Hematopoietic Stem Cells / Q000201:enzymology / Q000502:physiology*; D006801:Humans; D020014:K562 Cells; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics* / Q000378:metabolism; D012190:Retroviridae / Q000201:enzymology / Q000235:genetics*; D014161:Transduction, Genetic / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D019853:O(6)-Methylguanine-DNA Methyltransferase